Pharvaris N.V. (PHVS) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 36.2% versus a loss of 26.2%. Over five years, PHVS leads with a +96.8% price change compared with -77.1% for RXRX. Recursion Pharmaceuticals is the larger company by market cap ($2.34 billion vs $2.18 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | RXRX |
|---|---|---|
| Share price | $31.10 | $4.36 |
| Market cap | $2.18B | $2.34B |
| 1-day change | -0.06% | +10.38% |
| YTD return | +12.07% | +6.60% |
| 1-year return | +36.16% | -26.23% |
| 5-year return | +96.84% | -77.10% |
| EPS (TTM) | $-3.06 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $74.68M |
| Revenue growth (YoY) | — | +26.92% |
| Net income (latest FY) | $-25.99M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | — | -867.87% |
| Net margin | — | -863.35% |
| 52-week high | $43.25 | $7.18 |
| 52-week low | $20.65 | $2.77 |
| Distance from 52-week high | -28.09% | -39.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +84.47% | +65.60% |
| Average volume | 711.75K | 20.70M |
| Shares outstanding | 70.20M | 535.34M |
| Employees | 148 | 600 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed RXRX by 62.4 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Healthcare · Biotechnology · 148 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Healthcare · Biotechnology · 600 employees
PHVS vs RXRX FAQ
Which is bigger, Pharvaris N.V. or Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.34B compared with $2.18B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, PHVS or RXRX?
PHVS returned +36.16% over the past 12 months, compared with -26.23% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.